Zynex, Inc. (OTCMKTS:ZYXI) Files An 8-K Results of Operations and Financial ConditionITEM 2.02
On November13, 2017, Zynex,Inc. issued a press release announcing its financial results for the third quarter ended September30, 2017. The full text of the press release, together with the related unaudited financial and operating highlights, is furnished herewith as Exhibit99.1.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
d)Exhibits. The following exhibits are filed with this report.
ZYNEX INC ExhibitEX-99.1 2 tv480055_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Zynex Announces 2017 Third Quarter Earnings * Revenue grew 88% year over year to $6.8 million * Net income of $2.2 million increased 314% year over year; EPS $0.07 * Adjusted EBITDA of $3.1 million increased 319% year over year * Fifth consecutive quarter of net income,…To view the full exhibit click here
About Zynex, Inc. (OTCMKTS:ZYXI)
Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.
